Circulating Tumor Dna Clinical Trials
3 recruiting trials for Circulating Tumor Dna. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Circulating Tumor Dna clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Second Xiangya Hospital of Central South University (1), UMC Utrecht (1), GERCOR - Multidisciplinary Oncology Cooperative Group (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Genomic profiles detection (other, 1 trial), followed by circulating tumor DNA detection, ctDNA analysis after surgery.
Track Circulating Tumor Dna trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive...
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor...
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the...
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Circulating Tumor Dna, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Circulating Tumor Dna, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Circulating Tumor Dna, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.